InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,482.87
(
0.09%
)
US TECH 100
19,279.20
(
0.34%
)
Dow Jones
39,164.06
(
0.09%
)
Brent Oil
85.25
(
0.92%
)
Bitcoin
61,387.29
(
0.94%
)
Post# of 113951
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

researcher59

Send PM Follow Ignore
Followers 322
Posts 31991
Boards Moderated 22
Alias Born 12/30/2004

researcher59

Member Level

Re: SSKILLZ1 post# 107684

Wednesday, 11/08/2023 5:09:15 PM

Wednesday, November 08, 2023 5:09:15 PM

Post# of 113951
JAZZ (128) reports a slight miss and guides inline with estimates -

briefing -

Jazz Pharma misses by $0.09, reports revs in-line; reaffirms FY23 EPS guidance, guides FY23 revs in-line (128.24 -5.43) :

Reports Q3 (Sep) earnings of $4.84 per share, excluding non-recurring items, $0.09 worse than the FactSet Consensus of $4.93; revenues rose 3.3% year/year to $972.14 mln vs the $968.41 mln FactSet Consensus.
Co issues guidance for FY23, sees EPS of $18.15-$19.00, excluding non-recurring items, vs. $18.66 FactSet Consensus; sees FY23 revs of $3.75-$3.875 bln (from prior $3.725-$3.875 bln) vs. $3.83 bln FactSet Consensus.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up